The global fusion biopsy market size accounted for USD 738.94 million in 2024, grew to USD 802.72 million in 2025 and is predicted to hit around USD 1,690.87 million by 2034, representing a CAGR of 8.63% between 2024 and 2034. The North America fusion biopsy market size is calculated at USD 302.97 million in 2024 and is expected to grow at notable a CAGR of 8.75% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Fusion Biopsy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Fusion Biopsy Market, by Biopsy Route, 2024-2034
8.1.1. Transrectal
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Transperineal
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Fusion Biopsy Market, by End Use, 2024-2034
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Diagnostic Centers
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Ambulatory Care Centers
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.1.2. Market Revenue and Forecast, by End Use (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.1.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.2.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.2.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.3.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.4.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.5.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Biopsy Route (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End Use (2021-2034)
11.1. Eigen
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Koninklijke Philips N.V.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Hitachi Ltd.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. MedCom
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. ESAOTE SPA
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. KOELIS
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Focal Healthcare
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. BK Medical Holding Company, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Exact Imaging
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Biobot Surgical Pte Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample